Intomics A/S enters a new collaboration with a leading Swiss-based biopharmaceutical company to accelerate a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level through systems biology.

Intomics A/S and Actelion Pharmaceuticals Ltd have entered a new collaboration with the aim of developing a systems biology view of neurodegeneration. Intomics will assist Actelion with expertise, experience and tools in analyzing and advancing knowledge based on data specifically related to neurodegeneration. The purpose is to gain better molecular understanding of the pathological processes underlying neurodegeneration, with the long-term goal of facilitating better medical treatment for patients with neurodegenerative diseases. The specific terms related to the collaboration were not disclosed.

“Actelion has extensive and interesting experience in drug discovery and development of treatments for diseases with significant unmet medical needs. Drug discovery and development requires innovative attention, including informatics, bioinformatics and systems biology approaches, which is Intomic’s field of expertise. We are happy to expand our client portfolio to include Actelion, and we are very much looking forward to this collaboration” says Thomas S. Jensen, CEO of Intomics A/S.

About Intomics A/S:

Intomics is a contract research company that through partnering help clients solve the data-intensive challenges in developing tomorrow's medicines. Intomics has leading expertise in biomedical analysis and mining, bioinformatics, and systems biology. Using advanced data mining technologies, Intomics provide tailored solutions leading to increased success rates and cost savings in pharmaceutical research projects.

more about intomics A/S